WO2003006458A1 - Benzo [g] quinoline derivatives for treating glaucoma and myopia - Google Patents

Benzo [g] quinoline derivatives for treating glaucoma and myopia Download PDF

Info

Publication number
WO2003006458A1
WO2003006458A1 PCT/EP2002/007594 EP0207594W WO03006458A1 WO 2003006458 A1 WO2003006458 A1 WO 2003006458A1 EP 0207594 W EP0207594 W EP 0207594W WO 03006458 A1 WO03006458 A1 WO 03006458A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
acid addition
myopia
free base
addition salt
Prior art date
Application number
PCT/EP2002/007594
Other languages
French (fr)
Inventor
Rudolf Markstein
Peter Gull
Esteban Pombo Villar
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL365254A priority Critical patent/PL208284B1/en
Priority to IL15925502A priority patent/IL159255A0/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to EP02764648A priority patent/EP1419149B1/en
Priority to DE60233740T priority patent/DE60233740D1/en
Priority to BR0210894-1A priority patent/BR0210894A/en
Priority to AU2002328856A priority patent/AU2002328856B2/en
Priority to US10/483,310 priority patent/US7105528B2/en
Priority to NZ530314A priority patent/NZ530314A/en
Priority to CA2452920A priority patent/CA2452920C/en
Priority to HU0400833A priority patent/HUP0400833A3/en
Priority to MXPA03012039A priority patent/MXPA03012039A/en
Priority to JP2003512230A priority patent/JP5006505B2/en
Priority to KR1020047000232A priority patent/KR101069948B1/en
Priority to AT02764648T priority patent/ATE443060T1/en
Publication of WO2003006458A1 publication Critical patent/WO2003006458A1/en
Priority to IL159255A priority patent/IL159255A/en
Priority to NO20040059A priority patent/NO327549B1/en
Priority to HK04109018.5A priority patent/HK1066211A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Definitions

  • the present invention relates to novel benzo [g] quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
  • a and B are each H or form together an additional bond
  • X is CH 2 or CO
  • Y is O, S, NR 2 [ R 2 being H or (C 1-4 )alkyl] , CH 2 or O-CH 2 , and Ri is H or (C 1-4 )alkyl in free base or acid addition salt form.
  • the above-defined alkyl groups preferably represent methyl.
  • the X-Y-pyrimidine substituent preferably presents the configuration 3R.
  • X is preferably CH 2 .
  • Y is preferably O or S, even more preferably S.
  • R is preferably methyl, more preferably methyl in position 4 of the addressed pyrimidine.
  • a and B each represents H, X is CH , Y represents S and ⁇ is methyl.
  • the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby in a compound of formula II
  • A, B, X, Y and R ⁇ are as defined above and R 3 is (C ⁇ - )alkyl, the alkoxy group is converted into a hydroxy group, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.
  • R 3 is preferably methyl.
  • Acid addition salts may be produced from the free bases in known manner, and vice versa.
  • Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
  • the starting compounds of formula II wherein A and B are each H may be produced from the corresponding compounds of formula lll a
  • R 3 is as defined above, for example as described in Example 1.
  • R 3 is as defined above.
  • agents of the invention exhibit valuable pharmacological properties in animal tests and are therefore useful as pharmaceuticals.
  • the agents according to the invention effect a decrease on the intraocular pressure in rabbits, at concentrations of e.g. 10 to 100 ⁇ M.
  • Male rabbits of ca. 2.5 kg are fixed in cages leaving their heads free.
  • the solutions with the compound to be tested are applied to the right eye and the placebo solutions to the left eye (2 drops each, i.e. ca. 40 ⁇ l).
  • the eyes are firstly anaesthetized with a solution containing Novesine (0.4 %) and Fluorescein (0.05 %) and the ocular pressure is determined at various intervals after administration (10, 20, 30, 60, 90, 120, 180 and 240 minutes), whereby an applanation tonometer according to Goldberg is used.
  • the agents of the present invention exhibit a surprising strong efficacy in lowering the intraocular pressure (IOP) and an excellent duration of action. Moreover, they exhibit an excellent tolerability.
  • IOP intraocular pressure
  • the agents according to the invention are therefore in particular useful in the treatment of glaucoma and myopia.
  • a more preferred use is glaucoma treatment, lowering of IOP.
  • the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans , an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
  • the agents of the invention may be administered in free form or in pharmaceutically acceptable salt form.
  • Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
  • the present invention provides an agent of the invention for use as a pharmaceutical, e.g. in the treatment of glaucoma and myopia.
  • the present invention furthermore provides a pharmaceutical composition
  • a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier.
  • Such compositions may be formulated in conventional manner.
  • Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.
  • Agents according to the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.
  • they are applied topically to the eye in about 0.0001 to 2 %, preferably in about 0.001 to 0.5 %, and more preferably in about 0.01 to 0.1 % ophthalmological solutions.
  • the ophthalmic vehicle is such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
  • the pharmaceutically acceptable ophthalmic vehicle may be e.g. an ointment, vegetable oil, or an encapsulating material.
  • the present invention also provides an agent of the invention for use as a pharmaceutical in the treatment of glaucoma and myopia.
  • the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of glaucoma and myopia.
  • the present invention provides a method for the treatment of glaucoma and myopia in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • the present invention relates also to any compound disclosed in the working examples. It further relates to any independent and/or dependant claims disclosed infra.
  • Example 1 The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected. Example 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides a compound of formula I wherein A, B, X, Y and R1 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceutical agents for the treatment of glaucoma and myopia.

Description

BENZO 1 G ! QUINOLINE DERIVATIVES FOR TREATING GLAUCOMA AND MYOPIA
The present invention relates to novel benzo [g] quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
Figure imgf000002_0001
wherein
A and B are each H or form together an additional bond,
X is CH2 or CO,
Y is O, S, NR2 [ R2 being H or (C1-4)alkyl] , CH2 or O-CH2, and Ri is H or (C1-4)alkyl in free base or acid addition salt form.
The above-defined alkyl groups preferably represent methyl.
When A and B are each H, the X-Y-pyrimidine substituent preferably presents the configuration 3R.
X is preferably CH2.
Y is preferably O or S, even more preferably S. R is preferably methyl, more preferably methyl in position 4 of the addressed pyrimidine.
In a preferred embodiment A and B each represents H, X is CH , Y represents S and ^ is methyl.
In a further aspect the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby in a compound of formula II
Figure imgf000003_0001
wherein A, B, X, Y and R^ are as defined above and R3 is (Cι- )alkyl, the alkoxy group is converted into a hydroxy group, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.
The reaction can be effected according to known methods, e.g. using hydrobromide acid or boron tribromide. In formula II, R3 is preferably methyl.
Working up the reaction mixtures obtained according to the above process and purification of the compounds thus obtained may be carried out in accordance to known procedures.
Acid addition salts may be produced from the free bases in known manner, and vice versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
The starting compounds of formula II wherein A and B are each H may be produced from the corresponding compounds of formula llla
Figure imgf000004_0001
wherein R3 is as defined above, for example as described in Example 1.
The compounds of formula llla are known or may be produced in analogous manner to known procedures.
The starting compounds of formula II wherein A and B together form an additional bond may be produced from the corresponding compounds of formula lllb
π
Figure imgf000004_0003
i
Figure imgf000004_0002
wherein R3 is as defined above.
The compounds of formula lllb are known or may be produced in analogous manner to known procedures.
The compounds of formula I and their physiologically acceptable acid addition salts, referred to hereinafter as agents of the invention, exhibit valuable pharmacological properties in animal tests and are therefore useful as pharmaceuticals.
In particular, the agents according to the invention effect a decrease on the intraocular pressure in rabbits, at concentrations of e.g. 10 to 100 μM. Male rabbits of ca. 2.5 kg are fixed in cages leaving their heads free. The solutions with the compound to be tested are applied to the right eye and the placebo solutions to the left eye (2 drops each, i.e. ca. 40μl). The eyes are firstly anaesthetized with a solution containing Novesine (0.4 %) and Fluorescein (0.05 %) and the ocular pressure is determined at various intervals after administration (10, 20, 30, 60, 90, 120, 180 and 240 minutes), whereby an applanation tonometer according to Goldberg is used.
The agents of the present invention, in particular the preferred agents, exhibit a surprising strong efficacy in lowering the intraocular pressure (IOP) and an excellent duration of action. Moreover, they exhibit an excellent tolerability.
The agents according to the invention are therefore in particular useful in the treatment of glaucoma and myopia. A more preferred use is glaucoma treatment, lowering of IOP.
For the above mentioned indication, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans , an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
The agents of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
Accordingly the present invention provides an agent of the invention for use as a pharmaceutical, e.g. in the treatment of glaucoma and myopia.
The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention. Agents according to the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.
More preferably, they are applied topically to the eye in about 0.0001 to 2 %, preferably in about 0.001 to 0.5 %, and more preferably in about 0.01 to 0.1 % ophthalmological solutions.
The ophthalmic vehicle is such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
The pharmaceutically acceptable ophthalmic vehicle may be e.g. an ointment, vegetable oil, or an encapsulating material.
In accordance with the foregoing, the present invention also provides an agent of the invention for use as a pharmaceutical in the treatment of glaucoma and myopia.
Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of glaucoma and myopia.
In still a further aspect the present invention provides a method for the treatment of glaucoma and myopia in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
The present invention relates also to any compound disclosed in the working examples. It further relates to any independent and/or dependant claims disclosed infra.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected. Example 1
F3R.4aR.1 OaRM -methyl-SB-^ 4-methyl-1 ,3-pyrimidin-2yl rthiomethyl-6-hvdroxy-
1 ,2,3 ,4,4aα,5.10.1 Oaβ-octahvdrobenzorglquinoline
a) l3R.4aR.10aR1-1-methyl-3β-hvdroxymethyl-6-methoxy-1 ,2,3.4. 4aoc,5,10. 10aβ-octahvdrobenzorglquinoline
To a solution of 5.78g (20 M) [3R,4aR,10aR]-1-methyl-3β-methoxycarbonyl-6- methoxy-1,2,3,4,4aα,5,10,10aβ-octahydrobenzo[g]quinoline in 100 ml toluene, a solution of 12 ml SDBA (70 % in toluene, 42 mM) is added in drops under argon at room temperature within one hour. Then 10 ml NaOH (30 %) are added in drops to the ice cooled reaction mixture. The precipitated crystals are filtered off, washed with water and toluene and dried. The resulting title compound has a m.p. of 148°; [ ]20 D = -120° (c = 0.425 in ethanol).
b) r3R,4aR,10aRl-1-methyl-3β-mesyloxymethyl-6-methoxy-1,2,3,4,4a ,5,10. 10aβ-octahvdrobenzorqlqυinoline
12 ml (153 mM) methanesulfochloride are added in drops to a solution of 20 g (76.5 mM) of the compound obtained under a) in 150 ml pyridine at room temperature. The temperature is kept below 45° by ice cooling. After stirring for 2 hours at room temperature, the solution is adjusted to pH 7-8 with saturated KHCO3 solution at 0° and extracted with ethylacetate. After drying over Na2SO4, filtering and concentrating by evaporation, the title compound is obtained as beige crystals and directly used for the next step.
c) r3R.4aR,1 OaRI-1 -methyl-Sβ-*! 4-methyl-1 ,3-pyrimidin-2yl hiomethyl-6-methoxy- 1.2,3,4r4aα,5, 10,1 Oaβ-octahydrobenzorqlquinoline
A solution of 6 g (17.7 mM) of the compound obtained under b) and 3.4 g (27 mM) 2- mercapto-4-methyl-1,3-pyrimidin in 60 ml dimethylformamide is mixed with 6 ml 2N NaOH and stirred at 65° for 18 hours. The so obtained suspension is concentrated by evaporation. The crude product crystallises. The suspension is cooled to 5-10°, washed with ethylacetate and dried. Chromatography on silicagel with ethylacetate containing 10 % ethanol and 0.01 % NH3 yields the title compound as beige crystals. r3R.4aR,1 OaRI-1 -methyl-SB--! 4-methyl-1 ,3-pyrimidin-2yl l-thiomethyl-6-hvdroxy- 1 ,2.3,4,4aα,5,10,1 Oaβ-octahydrobenzorqlquinoline To a solution of 4.06 g (11 mM) of the product obtained under c) in 250 ml methylenechloride, 40 ml of boron tribromide (1 M in methylenechloride) are slowly added in drops at a temperature of -40°. The suspension is stirred for 2 hours at room temperature, neutralized with NH3 and extracted with a mixture of 150 ml methylenechloride and 100 ml isopropanol. After drying over Na2SO , filtering and concentration by evaporation, the title compound crystallises. The corresponding hydrochloride crystallises from methanol/ethanol 1:1 during evaporation. M.p. 254°; [ ]20 D= -90° (c = 0.540 in ethanol/water 1:1). CaoHssNaOS (HCI), MW=391.97.

Claims

CLAIMS:
1. A compound of formula I
Figure imgf000009_0001
wherein
A and B are each H or form together an additional bond,
X is CH2 or CO,
Y is O, S, NR [R2 being H or (C1-4)alkyl] , CH2 or O-CH2, and
Ri is H or (C1-4)alkyl in free base or acid addition salt form.
A process for the preparation of a compound of formula I as defined in claim 1 , or a salt thereof, which includes the step of converting, in a compound of formula II
Figure imgf000009_0002
wherein A, B, X, Y and Ri are as defined in claim 1 and R3 is (Cι- )alkyl, the alkoxy group into a hydroxy group and recovering the thus obtained compound of formula I in free base or acid addition salt form.
3. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of glaucoma and myopia.
5. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
6. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of glaucoma and myopia.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of glaucoma and myopia.
8. A method for the treatment of glaucoma and myopia in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.
PCT/EP2002/007594 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia WO2003006458A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
KR1020047000232A KR101069948B1 (en) 2001-07-09 2002-07-08 Benzo [G] Quinoline Derivatives for Treating Glaucoma and Myopia
NZ530314A NZ530314A (en) 2001-07-09 2002-07-08 Benzo [G] quinoline derivatives for treating glaucoma and myopia
EP02764648A EP1419149B1 (en) 2001-07-09 2002-07-08 Benzo[g]quinoline derivatives for treating glaucoma and myopia
DE60233740T DE60233740D1 (en) 2001-07-09 2002-07-08 BENZOEQUECHINOLINE DERIVATIVES FOR THE TREATMENT OF GLAUCOM AND SHORT-TERM
BR0210894-1A BR0210894A (en) 2001-07-09 2002-07-08 Benzo (g) quinoline derivatives
AU2002328856A AU2002328856B2 (en) 2001-07-09 2002-07-08 Benzo (G) quinoline derivatives for treating glaucoma and myopia
US10/483,310 US7105528B2 (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia
PL365254A PL208284B1 (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia
CA2452920A CA2452920C (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia
MXPA03012039A MXPA03012039A (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia.
HU0400833A HUP0400833A3 (en) 2001-07-09 2002-07-08 Benzo[g]quinoline derivatives for treating glaucoma and myopia, process for their preparation and pharmaceutical compositions containing them
JP2003512230A JP5006505B2 (en) 2001-07-09 2002-07-08 Benzo [G] quinoline derivatives for treating glaucoma and myopia
IL15925502A IL159255A0 (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia
AT02764648T ATE443060T1 (en) 2001-07-09 2002-07-08 BENZOAQUINOLINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA AND MIOPSIGHTEDNESS
IL159255A IL159255A (en) 2001-07-09 2003-12-08 Benzo [g] quinoline derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating glaucoma and myopia
NO20040059A NO327549B1 (en) 2001-07-09 2004-01-07 Benzo [G] quinoline derivatives for the treatment of glaucoma and myopia
HK04109018.5A HK1066211A1 (en) 2001-07-09 2004-11-15 Benzo (g) quinoline derivatives for treating glaucoma and myopia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116553 2001-07-09
EP01116553.7 2001-07-09

Publications (1)

Publication Number Publication Date
WO2003006458A1 true WO2003006458A1 (en) 2003-01-23

Family

ID=8177978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007594 WO2003006458A1 (en) 2001-07-09 2002-07-08 Benzo [g] quinoline derivatives for treating glaucoma and myopia

Country Status (26)

Country Link
US (1) US7105528B2 (en)
EP (1) EP1419149B1 (en)
JP (2) JP5006505B2 (en)
KR (2) KR101069948B1 (en)
CN (1) CN1293071C (en)
AR (1) AR036131A1 (en)
AT (1) ATE443060T1 (en)
AU (1) AU2002328856B2 (en)
BR (1) BR0210894A (en)
CA (1) CA2452920C (en)
DE (1) DE60233740D1 (en)
EC (1) ECSP024377A (en)
ES (1) ES2330732T3 (en)
HK (1) HK1066211A1 (en)
HU (1) HUP0400833A3 (en)
IL (2) IL159255A0 (en)
MX (1) MXPA03012039A (en)
MY (1) MY130656A (en)
NO (1) NO327549B1 (en)
NZ (1) NZ530314A (en)
PE (1) PE20030240A1 (en)
PL (1) PL208284B1 (en)
PT (1) PT1419149E (en)
RU (1) RU2300532C2 (en)
WO (1) WO2003006458A1 (en)
ZA (1) ZA200309642B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023258A1 (en) * 2003-09-05 2005-03-17 Novartis Ag Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11110110B2 (en) 2017-11-24 2021-09-07 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24415A (en) * 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512952A1 (en) * 1991-05-02 1992-11-11 Sandoz Ltd. Octahydrobenzo (G) quinoline
EP0659430A1 (en) * 1993-12-21 1995-06-28 Sandoz Ltd. Use of benzo[g]quinolines in the treatment of glaucoma and for the prevention of progressive atrophy of the optic nerve
WO1997003054A1 (en) * 1995-07-07 1997-01-30 Novartis Ag BENZO[g]QUINOLINE DERIVATIVES
WO1998001444A1 (en) * 1996-07-08 1998-01-15 Novartis Ag BENZO[g]QUINOLINE DERIVATIVES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262422A (en) 1991-05-02 1993-11-16 Sandoz Ltd. Octahydrobenzo[g]quinoline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512952A1 (en) * 1991-05-02 1992-11-11 Sandoz Ltd. Octahydrobenzo (G) quinoline
EP0659430A1 (en) * 1993-12-21 1995-06-28 Sandoz Ltd. Use of benzo[g]quinolines in the treatment of glaucoma and for the prevention of progressive atrophy of the optic nerve
WO1997003054A1 (en) * 1995-07-07 1997-01-30 Novartis Ag BENZO[g]QUINOLINE DERIVATIVES
WO1998001444A1 (en) * 1996-07-08 1998-01-15 Novartis Ag BENZO[g]QUINOLINE DERIVATIVES

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023258A1 (en) * 2003-09-05 2005-03-17 Novartis Ag Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
JP2007504198A (en) * 2003-09-05 2007-03-01 ノバルティス アクチエンゲゼルシャフト Composition comprising benzo [g] quinoline derivative and prostaglandin derivative
EP1859802A2 (en) * 2003-09-05 2007-11-28 Novartis AG Compositions comprising benzo(G)quinoline derivates and prostaglandin derivates
EP1859802A3 (en) * 2003-09-05 2007-12-19 Novartis AG Compositions comprising benzo(G)quinoline derivates and prostaglandin derivates
US11110110B2 (en) 2017-11-24 2021-09-07 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11707476B2 (en) 2017-11-24 2023-07-25 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of parkinson's disease
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US20220185839A1 (en) 2019-05-20 2022-06-16 H. Lundbeck A/S Process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
US11827665B2 (en) 2019-05-20 2023-11-28 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11851456B2 (en) 2019-05-20 2023-12-26 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11858954B2 (en) 2019-05-20 2024-01-02 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11866410B2 (en) 2019-05-20 2024-01-09 H. Lundbeck A/S Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diol

Also Published As

Publication number Publication date
MXPA03012039A (en) 2004-03-26
PL365254A1 (en) 2004-12-27
KR20040013126A (en) 2004-02-11
KR20100007983A (en) 2010-01-22
RU2004102398A (en) 2005-07-10
DE60233740D1 (en) 2009-10-29
NO20040059L (en) 2004-01-07
ZA200309642B (en) 2004-10-04
ES2330732T3 (en) 2009-12-15
MY130656A (en) 2007-07-31
NZ530314A (en) 2005-08-26
CA2452920C (en) 2010-03-30
NO327549B1 (en) 2009-08-10
US7105528B2 (en) 2006-09-12
HK1066211A1 (en) 2005-03-18
CN1293071C (en) 2007-01-03
ECSP024377A (en) 2004-08-27
AR036131A1 (en) 2004-08-11
PE20030240A1 (en) 2003-04-16
KR101069948B1 (en) 2011-10-04
PL208284B1 (en) 2011-04-29
JP2010024243A (en) 2010-02-04
EP1419149B1 (en) 2009-09-16
EP1419149A1 (en) 2004-05-19
PT1419149E (en) 2009-11-25
AU2002328856B2 (en) 2005-08-04
JP5006505B2 (en) 2012-08-22
HUP0400833A2 (en) 2004-07-28
HUP0400833A3 (en) 2010-03-29
CA2452920A1 (en) 2003-01-23
IL159255A0 (en) 2004-06-01
ATE443060T1 (en) 2009-10-15
CN1525969A (en) 2004-09-01
JP2004538278A (en) 2004-12-24
US20040171628A1 (en) 2004-09-02
RU2300532C2 (en) 2007-06-10
IL159255A (en) 2010-05-17
BR0210894A (en) 2004-06-22

Similar Documents

Publication Publication Date Title
JP2010024243A (en) Benzo[g]quinoline derivative for treatment of glaucoma and myopia
US20080255176A1 (en) Quinoline derivatives
AU2002328856A1 (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia
EP0912553B1 (en) BENZO[g]QUINOLINE DERIVATIVES
US5262422A (en) Octahydrobenzo[g]quinoline
EP1757601B1 (en) Quinoline derivatives and their use in glaucoma and myopia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200301134

Country of ref document: VN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002764648

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 159255

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/09642

Country of ref document: ZA

Ref document number: 200309642

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002328856

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/012039

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501355

Country of ref document: PH

Ref document number: 530314

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2452920

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003512230

Country of ref document: JP

Ref document number: 10483310

Country of ref document: US

Ref document number: 45/CHENP/2004

Country of ref document: IN

Ref document number: 1020047000232

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028138619

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002764648

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 530314

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002328856

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 530314

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020097025779

Country of ref document: KR